Today, Aytu BioPharma announced their intention to conduct a drug therapy trial for Vascular Ehlers-Danlos Syndrome. The VEDS Movement and The Marfan Foundation are thrilled to support this effort to investigate a medication that may potentially reduce life-threatening medical complications in VEDS. We anticipate providing education and awareness to physicians, individuals and families about details of this trial as they become available.
The trial will study the investigational oral compound, enzastaurin, for its inhibition of the protein kinase C (PKC) pathway. The PKC pathway has been implicated in the pathogenesis of VEDS in mouse models. Enzastuarin has been studied in over 40 human trials across a range of cancers including glioblastoma. The trial will investigate the ability of enzastaurin to reduce the severe complications of VEDS.
“The effectiveness of enzastaurin in reducing life-threatening complications of VEDS in mice was incredible,” said Katie Wright, Director of The VEDS Movement, “With the safety profile of enzastaurin known from previous trials in cancers, we are thrilled to find out if this reduction in life-threatening complications of VEDS translates to humans in this trial.”
The VEDS Movement will provide updates on the progress of trial details and provide any other relevant information as it becomes available. We encourage individuals and family members with VEDS to sign up for updates on The VEDS Movement website.
About The VEDS Movement
The VEDS Movement is dedicated to improving the quality of life and saving lives of individuals affected by Vascular Ehlers-Danlos Syndrome through research, patient support, education, and awareness. A division of The Marfan Foundation, the Movement has the support of a large, diverse Professional Advisory Board, consisting of leading experts across the country on VEDS, Marfan Syndrome, Loeys-Dietz, and related genetic aortic conditions. Learn more and get involved.